Sunday, August 6, 2017

August Newsletters Vosevi and Mavyret: Have We Reached the End of HCV Drug Development?

Vosevi and Mavyret
Like a kind man once said "It's a Beautiful Day in This Neighborhood." 

Welcome folks, the HCV community had some great news on Aug 3 when AbbVie's Mavyret (glecaprevir/pibrentasvir) was FDA approved and also in July when Gilead announced the FDA approval of Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir.) In addition the EMA granted marketing authorization for both Vosevi and Mavyret, in July as well.

Mavyret & Vosevi: News & Updates
You know what I love, a well organized list of noteworthy articles about Mavyret and Vosevi. Sit back, get comfortable, even grab a pair of slippers, before clicking on the above mentioned links.

Thank You
Thank you to all the good people who put out these informative newsletters and well written blogs each month. A special thank you to Don, for always tweeting about this blog, follow my handsome friend on Twitter @dcrocock, on Facebook, here.

Newsletters & Blogs
This index of August newsletters offer health tips and important information about both newly approved direct-acting antivirals, as do the following patient friendly blogs.

HIV and ID Observations
NEJM Journal Watch - An ongoing dialogue on HIV/AIDS, infectious diseases, all matters medical, and some not so medical.

Have We Reached the End of HCV Drug Development?
Paul E. Sax, MD
Two new HCV regimens gained FDA approval recently, bringing us closer to the end of this extraordinary phase of drug development.
Think about it — has ever been a more spectacularly rapid improvement in treatment of anything? If so, please let me know what that is. Remember, as recently as early 2013, highly toxic interferon-based therapy (with ribavirin and telaprevir or boceprevir) was still standard-of-care.
Begin here...

Médecins Sans Frontières/ Doctors Without Borders (MSF)
Médecins Sans Frontières (MSF) is an international, independent, medical humanitarian organisation. We offer assistance to people based on need, irrespective of race, religion, gender or political affiliation. Our actions are guided by medical ethics and the principles of neutrality and impartiality.

Fighting Hepatitis in Cambodia: The mid-point

At the half-way point of her assignment in Cambodia, Theresa reflects on what she's accomplished, and what she's learned about life as a doctor with...
Continue reading....

World Hepatitis Day

"Do I sound proud of our clinic? Well, that’s because I am proud. Every day we walk through a crowd of anxious patients to get to the clinic, and every day we confront apparently insurmountable obstacles, and yet every day we are getting people treated for hepatitis C."
Continue reading....

HEP - News & Blog Updates
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis. Offering unparalleled editorial excellence since 2010, Hep and Hep Magazine are the go-to source for educational and social support for people living with hepatitis.

Treatment News
FDA OKs AbbVie’s Mavyret for All Hepatitis C Genotypes
For first-timers to treatment with all genotypes and no cirrhosis, eight weeks of Maryvet is recommended; for those who have compensated cirrhosis, defined as Child-Pugh A, 12 weeks is recommended.

Hep C Cure Impact Greatest on Those With Advanced Fibrosis
A look at a large cohort of Canadians with HIV and hepatitis C also examined modifiable factors associated with a reduced risk of death.
Begin here....

Blog Updates
Vosevi: The Newest Hepatitis C Treatment on the Block
By Lucinda K. Porter, RN
Gilead Sciences’ Vosevi is one pill containing three drugs. All are direct-acting antivirals (DAAs) which means they directly interfere with hepatitis C virus replication. One drug, sofosbuvir (brand name Sovaldi), has been on the market since late 2013. It is a polymerase inhibitor. The second drug is velpatasvir, an NS5A inhibitor.

FDA Approves New Hepatitis C Treatment Vosevi for All Genotypes
By Connie M. Welch
Vosevi is a once a day, fixed dose combination pill to be taken at a scheduled time each day. Vosevi is recommended to take with food. If you need to take an antacid medicine that contains aluminum or magnesium, take it either four hours before or four hours after you take your dose of Vosevi.
Continue reading....

The National Viral Hepatitis Roundtable NVHR
The National Viral Hepatitis Roundtable is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance.

NVHR’s More than Tested Cured, Project Empowers Drug Users to Take Control of Their Health
The More than Tested, Cured project is a partnership between the National Viral Hepatitis Roundtable (NVHR), the Atlanta Harm Reduction Coalition (AHRC), the People’s Harm Reduction Alliance (PHRA) and the Urban Survivors Union (USU). These groups are working together to improve access to hepatitis C care faced by individuals who use drugs nationwide.

To view a list of all bloggers at HEP, please click here.

HEPATITISC.NET
At HepatitisC.net we empower patients and caregivers to take control of Hepatitis C by providing a platform to learn, educate, and connect with peers and healthcare professionals

Childhood and Hepatitis C
By Karen Hoyt
Hep C Treatment Approved for Children Finally a cure for kids! For those youngsters with hep C, the FDA gave out good news. Two of the drugs that have been used for...
Continue reading...

Tips and Life Hacks for Navigating Hepatitis C
Being diagnosed with hepatitis C and then navigating its symptoms and treatment can be overwhelming, daunting, and stressful. For those in the community trying to manage hepatitis C, tips and certain life..

View all blog updates, here.

United States
HCV Advocate
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.

In The Spotlight
A GUIDE TO: UNDERSTANDING HEPATITIS C 2017
The most important steps that people can take are to learn as much as they can about hepatitis C and work with their medical provider to stay as healthy as possible—and that should include seeking HCV treatment now. This Guide is meant to help you understand hepatitis C and provide some strategies to become healthier and live longer.
Download PDF

HCV Advocate - August Newsletter
At the top of the list is that a new combination of hepatitis C medications was approved by the Food and Drug Administration (FDA) to re-treat people who have not been cured with a previous course of certain direct-acting antiviral medications. Alan Franciscus includes HCV Drugs that offers a short overview of the FDA approval of Vosevi listed above. There is also a comprehensive overview of Vosevi that can be found on our Hep C Medications Blog. Lucinda K. Porter provides valuable information about moving on after being cured of hepatitis C and provides opinions from some of the leading experts on liver disease.

The New York City Hepatitis C Task Force
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.

August 2017 Hep Free NYC Newsletter
The NYS Department of Health has developed and released a guidelines on screening, diagnosis, and treatment of chronic Hep C infection for primary care providers.
Read the guideline here, newsletter, here.

Newsletter Archive

GI & Hepatology News
Over 17,000 gastroenterologists and hepatologists rely on GI & Hepatology News every month to cover the world of medicine with breaking news, on-site medical meeting coverage, and expert perspectives both in print and online. The official newspaper of the AGA Institute was launched in partnership with IMNG in January 2007.

August 2017
Under Liver Disease
Liver disease doubles risk of colorectal cancer
View all newsletters, here.

Canada
Weekly Bull
HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

Updates
Friday, August-4-17

All Issues: Weekly Bull

UK
British Liver Trust
The British Liver Trust is the leading UK liver disease charity for adults – we provide information and support; increase awareness of how liver disease can be prevented and promote early diagnosis; fund and champion research and campaign for better services.
The Trust has worked with The National Institute for Health and Care Excellence (NICE) in the development of the new quality standard on liver disease, published on 30 June 2017.  This quality standard covers identifying, assessing and managing chronic liver disease in children, young people and adults, and cirrhosis in young people and adults.
Begin here..

Hepatitis C Coalition
The Hepatitis C Coalition is a group of leading clinicians, patient organisations, professional groups, industry and other interested parties committed to the reduction of morbidity and mortality associated with hepatitis C and its eventual elimination.

Newsletter
New Zealand
The Hepatitis Foundation of New Zealand
The Hepatitis Foundation is a not-for-profit organisation which provides care for people living with hepatitis B. The Foundation provides a long-term follow-up programme for people living with chronic hepatitis B. This Programme provided Hepatitis B patients with ongoing monitoring and follow-up to help improve health outcomes.

August Updates
A leading liver specialist at Auckland Hospital is calling for Pharmac to expand funding for treatment of Hepatitis C to reduce deaths linked to the deadly disease.
Begin here...

A Little Doctor Humor From SERMO physicians & World Hepatitis Day 
The SERMO Community Blog provides a window into the important, and oftentimes entertaining, content being shared by SERMO physicians.

<--- Who is the stock image doctor?
A few one-liners:
“Patient: ‘You don’t look like you did on the website. I thought I would have a good looking doctor.’  – Neurology

“Why do pretend docs always fold their arms?” – Psychiatry

He is the father of the kids whose picture comes in your newly purchased picture frame.” – Pathology

World Hepatitis Day
In a poll gauging 5,000+ global physicians, SERMO asked doctors if they thought hepatitis B and/or C could be wiped out by 2030. While 52% of physicians did not think that hepatitis B or C can be cured by 2030, 28% felt confident that both could be eliminated. 11% thought that only hepatitis C could be eliminated, and 9% of physicians thought only hepatitis B could be eliminated.
Continue reading this article or check out the blog, here.

Just So You Know
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading full text articles about the treatment and management of hepatitis C.

Always
Tina

No comments:

Post a Comment